titan pharmaceuticals inc (TTNP:OTC BB)
titan pharmaceuticals inc (TTNP) Snapshot
|
Open
$0.55
|
Previous Close
$0.55
|
|
|
Day High
$0.55
|
Day Low
$0.54
|
|
|
52 Week High
02/5/13 - $2.53
|
52 Week Low
05/1/13 - $0.32
|
|
|
Market Cap
45.4M
|
Average Volume 10 Days
1.1M
|
|
|
EPS TTM
$-0.08
|
Shares Outstanding
82.5M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
titan pharmaceuticals inc (TTNP) Related Businessweek News
No Related Businessweek News Foundtitan pharmaceuticals inc (TTNP) Details
Titan Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing proprietary therapeutics for the treatment of serious medical disorders in the United States. The company offers Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. It is involved in developing Probuphine, an investigational subdermal implant for the treatment of opioid dependence. The Probuphine utilizes the company’s novel, proprietary drug delivery technology, ProNeura, which is used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
titan pharmaceuticals inc (TTNP) Top Compensated Officers
titan pharmaceuticals inc (TTNP) Key Developments
Titan Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2013. The net income for the quarter ended March 31 was approximately $6 million or about $0.08 per share compared to a net loss of about $5.2 million or $0.09 per share for the comparable period in 2012. Net income in the quarter consisted of licensing revenue of approximately $3.8 million, resulting from the amortization of the nonrefundable upfront license fee of $15.75 million. This is related to licensing agreement with Braeburn for the exclusive U.S. and Canadian commercialization rights for Probuphine. The company also generated royalty revenues on the sales of Fanapt during the 3-month period ended March 31, 2013, of approximately $1.4 million compared to about $1.2 million for the comparable period in 2012. The company generated no grant revenues during the quarter compared to about $42,000 for the period in 2012.
Effective May 17, 2013, Titan Pharmaceuticals Inc. will change its OTC Bulletin Board stock ticker symbol to TTNP from TTNP.E.
Effective May 16, 2013, Titan Pharmaceuticals Inc. will change its OTC Bulletin Board stock ticker symbol to TTNP.E from TTNP.
| Recently Viewed | |||
| TTNP:US | $0.55 USD | 0.00 |  |
| Company | Last | Change |
| Alkermes PLC | $31.98 USD | +0.94 |
| Celgene Corp | $123.50 USD | +0.38 |
| Eisai Co Ltd | ¥4,430 JPY | -50.00 |
| Reckitt Benckiser Group PLC | 4,849 GBp | +21.00 |
| View Industry Companies | ||
Industry Analysis
TTNP
Industry Average
| Valuation | TTNP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.9x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.3x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Northglenn, CO | Office DepotPosted: Mar 01
Sponsored Financial Commentaries
Sponsored Links
To contact TITAN PHARMACEUTICALS INC, please visit www.titanpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
